SL1122-37, a Novel Derivative of Sorafenib, Has Greater Effects Than Sorafenib on the Inhibition of Human Hepatocellular Carcinoma (HCC) Growth and Prevention of Angiogenesis

BioScience Trends - Japan
doi 10.5582/bst.2013.v7.5.237
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Related search

Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
2015English

Sorafenib for Advanced Hepatocellular Carcinoma (HCC): Impact of Rationing in the United Kingdom.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Protein Disulfide Isomerase Inhibition Synergistically Enhances the Efficacy of Sorafenib for Hepatocellular Carcinoma

Hepatology
MedicineHepatology
2017English

Can We Use Sorafenib Targeted Therapy for Advanced Hepatocellular Carcinoma (HCC) Child Pugh B

HPB
HepatologyGastroenterology
2016English

Inhibition of Cyclin-Dependent Kinase 5 - A Novel Strategy to Improve Sorafenib Response in HCC Therapy

Hepatology
MedicineHepatology
2018English

A miR-7/GAS6/TYRO3 Axis Regulates the Growth and Invasiveness of Sorafenib-Resistant Cells in Human Hepatocellular Carcinoma

Hepatology
MedicineHepatology
2017English

Effect of Sorafenib on Des‑γ‑carboxyprothrombin Secretion by a Human Hepatocellular Carcinoma Cell Line

Oncology Letters
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy